Original article. Correlation of FcγRIIIa polymorphisms and responses to rituximab in Thai population

1. Zhong Y. Non-Hogkin’s lymphoma: what primary care professionals need to know. J Nurse Pract. 2006; 2:309-15.10.1016/j.nurpra.2006.03.017Open DOISearch in Google Scholar

2. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. The Lancet Oncol. 2004; 5: 341-53.10.1016/S1470-2045(04)01490-1Open DOISearch in Google Scholar

3. Lu P. Staging and classification of lymphoma. Semin Nucl Med. 2005; 35:160-4.10.1053/j.semnuclmed.2005.02.002Open DOISearch in Google Scholar

4. Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo‘ V, et al. Treatment of B-cell non-Hodgkin’s lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol. 2001; 37: 13-25.10.1016/S1040-8428(00)00069-XOpen DOISearch in Google Scholar

5. Chinn P, Braslawsky G, White C, Hanna N. Antibody therapy of non-Hodgkin’s B-cell lymphoma. Cancer Immunol Immunother. 2003; 52: 257-80.10.1007/s00262-002-0347-6Search in Google Scholar

6. Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C R Biol. 2006; 329: 241-54.10.1016/j.crvi.2005.12.006Search in Google Scholar

7. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: A target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005; 4: 526-31.10.1016/j.autrev.2005.04.004Open DOISearch in Google Scholar

8. Foran JM. Antibody-based therapy of Non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol. 2002; 15: 449-65.10.1053/beha.2002.0222Open DOISearch in Google Scholar

9. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Hematol J. 2007; 67: 5-14.Search in Google Scholar

10. Weiner GJ, Link BK. Antibody therapy of lymphoma. Adv Pharmacol. 2004; 51: 229-53.10.1016/S1054-3589(04)51010-4Search in Google Scholar

11. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. New Engl J Med. 2008; 359: 613-26.10.1056/NEJMra070887518687642Search in Google Scholar

12. Cohen-Solal JFG, Cassard L, Fridman WH, Sautès- Fridman C. Fcã receptors. Immunol Lett. 2004; 92: 199-205.10.1016/j.imlet.2004.01.01215081612Open DOISearch in Google Scholar

13. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol. 2007; 19: 239-45.10.1016/j.coi.2007.01.00517291742Open DOISearch in Google Scholar

14. Ravetch JV, Perussia B. Alternative membrane forms of FcγRIII (CD16) on human natural killer cells and neutropils. Journal Experimental Medicine. 1989; 170: 481-97Search in Google Scholar

15. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005; 304: 88-99.10.1016/j.jim.2005.06.01816109421Search in Google Scholar

16. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell M, et.al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006; 108: 2648-54.10.1182/blood-2006-04-020057189559716825493Open DOISearch in Google Scholar

17. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: A target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005; 4: 526-31.10.1016/j.autrev.2005.04.00416214090Open DOISearch in Google Scholar

18. Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW, et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res. 2004; 64: 5825-29.10.1158/0008-5472.CAN-04-108815313926Open DOISearch in Google Scholar

19. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcg receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006; 203: 743-53.10.1084/jem.20052283211822716520392Search in Google Scholar

20. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000; 6: 443-6.10.1038/7470410742152Open DOISearch in Google Scholar

21. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcãRIIIa gene. Blood. 2002; 99: 754-8.10.1182/blood.V99.3.75411806974Open DOISearch in Google Scholar

22. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004; 64:4664-9.10.1158/0008-5472.CAN-03-286215231679Open DOISearch in Google Scholar

23. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal Clin Oncol. 2003; 21:3940-7.10.1200/JCO.2003.05.013Open DOISearch in Google Scholar

24. Weng WK, Weng WK, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk lymphoma. 2009; 50:1494-500.10.1080/10428190903128660Search in Google Scholar

25. Mitrovic Z, Aurer I, Radman I, Ajdukovic R, Sertic J, Labar B. FcgammaRIIIA and FcgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica. 2007; 92:998-9.10.3324/haematol.10327Open DOISearch in Google Scholar

26. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006; 108: 2720-5.10.1182/blood-2006-01-009480Open DOISearch in Google Scholar

27. Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, et al. FCGR3A and FCGR2Apolymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005; 105: 289-91.10.1182/blood-2004-02-0651Search in Google Scholar

28. Farag SS, Flinn IW, Modali R, Tibullo D, Salmoiraghi S, Rossi A, et.al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004; 103:1472-4.10.1182/blood-2003-07-2548Search in Google Scholar

29. Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, et al. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods. 2000; 242: 127-32.10.1016/S0022-1759(00)00240-4Search in Google Scholar

30. Torkildsen O, Utsi E, Mellgren SI, Harbo HF, Vedeler CA, Myhr KM. Ethnic variation of Fcg receptor polymorphism in Sami and Norwegian populations. Immunology. 2005; 115:416-21.10.1111/j.1365-2567.2005.02158.x178215615946259Search in Google Scholar

31. Cheson BD, Pfistner B, Bruce D, Juweid MD, Gascoyne RD, Specht L, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-86.10.1200/JCO.2006.09.240317242396Open DOISearch in Google Scholar

32. Wu J, Edberg JC, Radecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptorfunction and predisposes to autoimmune disease. J Clin Invest. 1997; 100:1059-70.10.1172/JCI1196165082809276722Open DOISearch in Google Scholar

33. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AEG, de Haas M. FcRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcRIIIa-48L/R/H phenotype. Blood. 1997; 90:1109-14.10.1182/blood.V90.3.1109Search in Google Scholar